Shareholding disclosure

Cosmo Pharmaceuticals NV, Amsterdam

Declared position

8.1%

Threshold

Crossed downwards

Timeline

Published

28.01.2022

Transaction

17.12.2021

Transfer date

17.12.2021

Voting rights breakdown

Voting rights acquired4.82%

Voting rights sold8.1%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TAM1R00034

Beneficial owner

Cosmo Pharmaceuticals NV, Amsterdam

Declared address

Cosmo Pharmaceuticals NV, Amsterdam

Sale of own shares

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

Cosmo Pharmaceuticals NV, Amsterdam

Cosmo N.V.28.01.2022TAM1R00034

Disclosure summary

Cosmo Pharmaceuticals NV, Amsterdam disclosed a holding in Cosmo N.V. on the disposal side, published by SIX Exchange Regulation on 28.01.2022, at 8.1% of voting rights. Notice category: Single shareholder.

Disclosed position

8.1%

Voting rights sold

Voting rights acquired4.82%

Voting rights sold8.1%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

Cosmo Pharmaceuticals NV, Amsterdam disclosed a holding in Cosmo N.V., published on 28.01.2022.

Publication date28.01.2022

Transaction date17.12.2021

Transfer date17.12.2021

Issuing companyCosmo N.V.

Beneficial ownerCosmo Pharmaceuticals NV, Amsterdam

Declared addressCosmo Pharmaceuticals NV, Amsterdam

CategorySingle shareholder

Voting rights acquired4.82%

Voting rights sold8.1%

Below threshold0%

ExchangeXSWX

Notification IDTAM1R00034

Conditions

Sale of own shares

Source: SIX Exchange Regulation · Publication date: 28.01.2022

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open